(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite ...
CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) ...
Needham upgraded Gilead Sciences (NASDAQ:GILD) to Buy from Hold on Friday, citing a physical survey to suggest that the company’s new twice-yearly injectable for HIV prevention, Yeztugo, is on track ...
MedPage Today on MSN
CDC Backs Twice-Yearly Injectable for HIV Prevention
The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...
Calgary-based virtual pharmacy PurposeMed is completing its U.S. expansion this month, bringing its popular Freddie service ...
Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not to add the former’s new HIV prevention drug, Yeztugo (lenacapavir), to its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback